Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage

Stopped early · Phase 1

Conditions studied: Intracerebral Hemorrhage

In brief

This study employs a modified continual reassessment method (mCRM) design to estimate the maximum tolerated dose (MTD) of PF-05230907, defined as a target toxicity rate of 15% based on treatment emergent thromboembolic and/or ischemic events (TIEs). The mCRM design utilizes Bayesian methodology to continuously learn the dose-toxicity relationship, which is characterized by a parametric model. Subjects with a diagnosis of ICH (determined by computed tomography) will be enrolled in cohorts of 3. The total length of time planned for study participation is approximately 3 months; 6.0 hours for screening, a single dose administration with a 4-day minimum hospital confinement period and follow-up visits through Day 91. Severity of adverse events (AEs) and serious adverse events (SAEs) will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. All subjects who receive PF-05230907 are evaluable for TIEs. The determination of MTD using mCRM modeling will be based on TIEs which occur through 7 days post-dose (Day 8).

Key facts

Study ID

NCT02687191

Run by

Pfizer

People needed

21

Starts

2016-11-01

Expected to finish

2018-01-01

Last updated by the study team

2019-04-17

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ICH as documented by CT scan within 6.0 hours of symptom onset
• Baseline ICH volume > 5mL and < 60 mL

You may not qualify if…

• Deep coma (Glasgow Coma Scale < 6)
• Modified Rankin Score > 3 prior to ICH onset
• Known history of schemic, vaso-occlusive or thrombotic events within 6 months prior to screening
• Known prothrombotic disorders
• Known secondary ICH related to aneurysm, arteriovenous malformation, subarachnoid hemorrhage, trauma, or other causes. CT angiography, MR, or other diagnostic studies obtained as part of the standard of care may be used to assess eligibility.
• Known use of oral anticoagulant(s)
• Known use of low-molecular weight heparin or heparin

Where it is running

• Barnes Jewish Hospital — St Louis, Missouri, United States
• Washington University, — St Louis, Missouri, United States
• James Cancer Hospital and Solove Research Institute — Columbus, Ohio, United States
• The Ohio State University Wexner Medical Center — Columbus, Ohio, United States
• Martha Morehouse Medical Plaza — Columbus, Ohio, United States
• The Ottawa Hospital — Ottawa, Ontario, Canada
• Montreal Neurological Institute and Hospital — Montreal, Quebec, Canada
• Hospital Universitari Germans Trias i Pujol — Badalona, Barcelona, Spain
• Hospital Clínico Universitario de Santiago de Compostela, Area Neurovascular-Neurologia — Santiago de Compostela, LA Coruna, Spain
• Hospital Vall d'Hebron, Unidad de Ictus — Barcelona, Spain
• Hospital Universitari Dr. Josep Trueta IDIBGI, Department Neurology — Girona, Spain
• Hospital Universitario Ramon y Cajal — Madrid, Spain
• University College Hospital — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.